FLT3: AML mutation testing

eagle-i ID

Resource Type

Properties

1. Resource Description

   "Kinase activating mutations of the FLT3 gene occur in a significant subset of acute myelogenous leukemias (AMLs) and confer a poor prognosis. The most common mutation (and the one detected in our lab) is an internal tandem duplication (ITDs) in exon 11 of the FLT3 gene (juxtamembrane domain), present in ~20-30% of all AMLs. If present, novel targeted therapies directed at this activated tyrosine kinase may be of clinical benefit."

2. Resource Description

   "Other terms: AML: acute myelogenous leukemias PCR-based study Tyrosine kinase gene Exon 11 of the FLT3 gene Juxtamenbrane domaine"

3. Resource Description

   "Specimen: ACD or EDTA whole blood; Bone marrow (fresh, unfixed) Handling: Transport at room temperature to arrive at the Molecular Diagnostic Center within 24 hours; if sample cannot arrive within 24 hours, refrigerate until sample can be transported, then transport at room temperature. Special Requirement: In order to detect FLT3 mutations, acceptable specimens of blood or bone marrow must have a minimum of 20% blast cells. Samples with less than 20% blasts will not be analyzed. A copy of the CBC w/diff or a Hematopathology report showing blast cell load would be ideal."

4. Resource Description

   "Synonyms: FLT, FLT3, AML mutation, ITD (internal tandem duplications) mutation, FLT3 mutation"

5. Additional Name

   FLT3: acute myelogenous leukemias mutation testing

6. Contact

   Richards, Carolyn Sue, PhD

7. Service Provided by

   Molecular Diagnostic Center

8. Website(s)

   http://www.ohsu.edu/pathology/wardman/forms/flt3info.pdf